• DAEHWA Pharm’s corrected notice extends the disclosure-violation designation decision deadline to Dec. 16, 2026, from Nov. 4, 2026.
• The Nov. 3 correction cites the need for additional review of the disclosure violations.
• The proposed designation concerns one disclosure reversal involving a sales-and-supply contract termination and one failure to disclose the termination promptly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DAEHWA Pharm. Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261103900418), on November 03, 2026, and is solely responsible for the information contained therein.